An observational study in Liver Neoplasm, sponsored by Central Hospital, Nancy, France. Recruiting at 1 site in France. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Central Hospital, Nancy, France · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 93 studies in Liver Neoplasms with a site in France — 16 open to participants now, 28 under way, 4 of them phase 3. Liver Neoplasms · France.
Among the 93 studies in Liver Neoplasms with a site in France, this one is the 21st largest by planned enrollment of the 26 observational ones that give a count, is one of 3 that started in 2026, is one of 26 observational ones, reaches primary completion later than 11 of the 27 other live ones, and was the 92nd registered.
1,348 studies on the registry are indexed under Liver Neoplasms; 337 are open to participants now.
Browse Liver Neoplasms studies →16 of the 93 studies in Liver Neoplasms with a site in France are open now. Recruiting first, the newest first:
Mark C Burgmans, MD PhD · Sites in France, Netherlands
Ages 18+
University Hospital, Lille · Sites in France
Ages 18+
Centre Hospitalier Universitaire Dijon · Sites in France
Ages 18+
Federation Francophone de Cancerologie Digestive · Sites in France
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 244 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 70 (29%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
93 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 28 · Phase 3 21
First in 1999; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is below the median of 200 across 344 observational studies indexed under Liver Neoplasms.
Median enrollment 129 across the 66 interventional studies, 303 across the 26 observational. Of the 60 that completed or were terminated, 22 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 93 have an industry lead sponsor. The 10 most frequent:
Central Hospital, Nancy, France is the lead sponsor of 801 studies on the registry; 188 are open to participants now.
Central Hospital, Nancy, France has 1 study filed under Liver Neoplasms — fewer than ten, so there is no comparison to draw.
7 of the studies in Liver Neoplasms with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03408665Centre Oscar LambretStereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer | 2026-12-01 |
| NCT02954094Target PharmaSolutions, Inc.A Longitudinal Observational Study of the Natural History and Management of Patients With HCC | 2027-02 |
| NCT04008797Eisai Inc.A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | 2027-03-31 |
| NCT06923761Grey Wolf TherapeuticsEMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1) | 2027-04-30 |
| NCT05063565Boston Scientific CorporationTheraSphere With Durvalumab and Tremelimumab for HCC | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 93 studies in Liver Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Microwave ablation is a minimally invasive technique whose planning relies on manufacturer tables derived from ex vivo models that do not account for patient or tumor-specific factors. In clinical practice, the actual ablation volume often differs from the planned volume due to liver characteristics, vascular proximity, and tumor biology.
This study aims to assess the variability between ablation small axis during percutaneous microwave ablation of liver lesions. The influence of patient-related (fibrosis, steatosis, portal flow) and tumor-related factors (location, histology, prior treatment) will be evaluated. Small axis and volume will be compared with volumes measured on immediate post-procedural CT and on CT/MRI at 6-12 weeks, accounting for expected tissue shrinkage.
Adult patients treated with percutaneous hepatic microwave ablation under CT or ultrasound guidance for one or more liver lesions with followed up imaging availables
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Small final ablation axis measured on the post-procedure imaging modality considered to be the most reliable.
The final short axis will preferably be measured (in mm) on MRI at 6-12 weeks. If inter-patient variability in volume shrinkage exceeds 5%, the modality with the lowest relative variability (usually the immediate CT scan) will be used as the reference for estimating the final volume.
Time frame: 12 weeks
Ran from Feb 2026 to primary completion in Jul 2026, 5 months.
Completion moved once since we started tracking on Sep 25, 2026: Jul 2026 → Dec 2026, on Oct 21, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital, Nancy, France →